Skip to content

Genetic toxicology of lysergic acid diethylamide (LSD-25)

Maimon M. Cohen, Yosef Shiloh

Mutation Research/Reviews in Genetic Toxicology 1977 DOI: 10.1016/0165-1110(77)90003-3 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Review Peer reviewed
Topics LSD
Keywords Toxicology Clastogen Hallucinogen Psychotomimetic Genetics Micronucleus test Pharmacology
Citations 28
Key findings Based on available data, no clear conclusions can be drawn about LSD's clastogenicity, mutagenicity, teratogenicity, or oncogenicity, though it is not teratogenic in humans and is at best a weak mutagen.

Abstract

The acute and the chronic psychotomimetic potentials of the hallucinogen lysergic acid diethylamide (LSD-25) have been recognized for almost 40 years. That additional types of the biological effects should have come under scrutiny was directly attributable to widespread use and abuse of this drug on a world-wide basis. Although "genetic toxicology" encompasses a broad spectrum of disciplines, including many areas of highly specialized research, perhaps the most germane, and those on which this review has concentrated, are Clastogenicity, Mutagenicity, Teratogenicity and Oncogenicity. Based on our current understanding and interpretation of the available data, the genetic toxicology of LSD provides an excellent example of Newton's "third law of motion", e.g., to every force there is an equal and opposite reaction force. From the published material it is impossible to draw clear cut conclusions regarding any of the above "problem areas" in spite of the considerable scientific effort invested. Most of the in vitro studies performed on the clastogenicity of LSD indicate either suppression of mitosis or enhanced chromosome damage. However, extrapolation of such results to the in vivo situation is very difficult. With regard to in vivo human use of the drug, no concensus is attainable as to chromosome breakage and the inconsistencies within and between studies remain inexplicable. However, several of the "controlled" investigations assessing the in vivo effect of chemically pure LSD suggest a transient increase in lymphocyte chromosome breakage. On the other hand, the results of cytogenetic studies on experimental animals are contradictory. Although human studies are nonexistent, in those experimental organisms tested, using accepted techniques, LSD proved to be, at best, a weak mutagen, if mutagenic at all. Teratogenicity studies in animals are confusing due to the multitude of organisms and plethora of discriminant parameters studied. However, with regard to man there has been ample opportunity and one can conclude that LSD is not teratogenic. As to the drug's oncogenic potential, the 3 reported cases of leukemia in LSD users are most likely the result of coincidence.

Comparable studies

Other narrative reviews on LSD, most cited first.

Study Year Design Participants
Study of a New Schizophrenomimetic Drug—Sernyl 1959 Review
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population 2019 Integrative review
The Pharmacology of Lysergic Acid Diethylamide: A Review 2008 Review
Serotonin research: contributions to understanding psychoses 2008 Review
ADVERSE REACTIONS TO PSYCHEDELIC DRUGS. A REVIEW OF THE LITERATURE 1984 Review

Citations in the library

Cited by 7

and 2 more in the library

Cites 28

and 23 more in the library

Related reading

Explore topics

LSD